1.1 Ibrutinib is recommended as an option for treating relapsed or refractory mantle cell lymphoma in adults, only if:
they have had only 1 previous line of therapy and
the company provides ibrutinib with the discount agreed in the commercial access agreement with NHS England.
1.2 This recommendation is not intended to affect treatment with ibrutinib that was started in the NHS before this guidance was published. People having treatment outside this recommendation may continue without change to the funding arrangements in place for them before this guidance was published, until they and their NHS clinician consider it appropriate to stop.